Dasatinib (Sprycel) medicines are generally used to
treat people with chronic myeloid leukemia and people with acute lymphoblastic
leukemia who have been tested positive for the Philadelphia chromosome (Ph+).
Developed by Bristol-Myers Squibb Company, Dasatinib has been approved by the
FDA for the treatment of pediatric patients aged one-year-old with newly
diagnosed Ph+ acute lymphoblastic leukemia in combination with chemotherapy.
The clinical trials have shown positive results with increased safety and
efficacy. The most common side-effects of Dasatinib in children with
chemotherapy include swelling, pain, fever, nausea, and diarrhea.
The report
provides a comprehensive understanding of the drug, covering all the API
manufactures and its details in the 7 major markets which includes EU5 (U.K.,
Spain, Germany, Italy and France), U.S., and Japan. It covers all patents and
strategic developments reported in this drug area. It highlights the historical
and forecasted sales along with the market scenario, market competition and the
historical and emerging therapies. The report is inclusive of SWOT and PESTLE
analysis, depending on the information availability.
Request to Get the Sample Pages at:
Moreover,
the report also provides a comprehensive understanding of the pipeline
activities of the drug candidate under various stages of development, with
detailed analysis of pipeline and clinical trials. Pipeline analysis of drug by
phases includes product description and development activities including
information about clinical results, designations, collaborations, licensing,
grants, technology and others.
